メタボリックサージェリー Clinical Update

出版社： メディカ出版
著者：
発行日： 2020-10-01
分野： 臨床医学：外科  >  消化器外科学
ISBN： 9784840472579
電子書籍版： 2020-10-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

12,100 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

12,100 円(税込)

購入する

商品紹介

肥満症診療の初学者や、メタボリックサージェリーを導入する施設のスタッフ、そしてより安全な治療のための知識習得や技術向上に必須のテキストブック。各分野のスペシャリストが集結して2017年刊行『肥満・糖尿病の外科治療』をアップデートし、肥満症研究の内容も充実し、装い新たに刊行。手術手技のコツとピットフォールは解説に加え、Web手術動画（計約86分）で繰り返し確認できる。

目次

  • 表紙
  • 本書について
  • 巻頭言
  • CONTENTS
  • 執筆者一覧
  • 略語一覧
  • 第1章 高度肥満症の病態と治療
  • 1 将来を見据えた肥満症治療
  • 2 高度肥満症の病態
  • 3 高度肥満症の診断
  • 4 高度肥満に見られやすい精神疾患
  • 5 肥満症に対するわが国の取り組みと外科治療
  • 6 わが国における肥満の現状とメタボリックサージェリーを取り巻く課題 - 肥満2型糖尿病へ臨床応用 -
  • 7 肥満症治療と医療安全
  • 第2章 高度肥満症に対する外科治療前の管理
  • 1 術前減量プログラムと周術期栄養管理
  • 2 運動療法
  • 3 薬物療法
  • 4 行動療法
  • 5 肥満患者への心理療法
  • Questions 肥満外科対象者で問題となる異常な食行動にはどのようなものがありますか ?
  • Questions 肥満外科患者に, 認知行動療法を実施するタイミングはいつが適切ですか ?
  • 6 術前の精神心理社会面の評価と準備
  • Questions 精神疾患をもつ患者は, メタボリックサージェリー適応外ですか ?
  • Questions 専門家がいない施設での精神心理社会面の評価はどのようにしたらよいですか ?
  • 7 2型糖尿病患者の注意点
  • 8 高度肥満症に合併する閉塞性睡眠時無呼吸症候群
  • 第3章 メタボリックサージェリーの実際
  • 1 チーム医療構築の重要性
  • 2 外科紹介のタイミングと症例検討会
  • 3 看護師の役割
  • 4 肥満患者の麻酔管理
  • Questions Rampとは
  • 5 手術適応
  • 6 手術の種類
  • 7 手術手技
  • (1) 腹腔鏡下ルーワイ胃バイパス術 ( LRYGB )
  • (2) 腹腔鏡下スリーブ状胃切除術 ( LSG )
  • (3) 腹腔鏡下スリーブ状胃切除術 + 十二指腸空腸バイパス術 ( LSG - DJB )
  • (4) メタボリックサージェリー後の修正手術
  • 8 周術期管理
  • 9 術後栄養管理とフォローアップ
  • 10 合併症とその対処法
  • Questions 肺塞栓予防はどうしていますか ?
  • Questions 縫合不全治療において, 最も重要な点は何ですか ?
  • 11 術後の心理変化とメンタルのサポート体制
  • Questions 術後の心理的変化で注意すべき症状はありますか ? また, どのように声をかければよいでしょうか ?
  • 12 患者サポートグループの重要性
  • Questions サポートグループはただ患者が集まって話をすればよいのでしょうか ? 正しいサポートグループの実施方法はあるのでしょうか ?
  • 13 リバウンド患者の特徴と対応
  • 14 治療困難事例への対処
  • 15 安全なメタボリックサージェリーの普及を目指した取り組み
  • 第4章 メタボリックサージェリーの改善メカニズムと効果
  • 1 糖尿病に対する改善機序
  • 2 糖尿病に対する効果
  • 3 メタボリックサージェリー後の持続血糖モニタリング ( CGM ) による評価
  • Questions 後期ダンピング症候群とは ?
  • 4 閉塞性睡眠時無呼吸症候群 ( OSAS ) に対する効果
  • Questions 高度肥満者でOSASを疑う症状, 所見にはどのようなものがあるでしょうか ?
  • Questions 携帯型睡眠呼吸検査によるOSAS診断では不十分でしょうか ?
  • 5 肥満関連腎臓病に対する効果
  • 6 非アルコール性脂肪性肝疾患に対する効果
  • 7 肥満と心不全
  • 8 産婦人科疾患に対する効果
  • 第5章 肥満症研究とトピックス
  • 1 腸内細菌叢と肥満症
  • 2 臓器連関によるエネルギー・糖代謝調節
  • 3 ヘパトカインと肥満・糖尿病
  • 4 がんと肥満・糖尿病
  • 5 高齢者高度肥満症患者の外科治療
  • 6 肥満・糖尿病の予防
  • 索引
  • Web手術動画の視聴方法
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 高度肥満症の病態と治療

P.4 掲載の参考文献
1) 平成28・29年度厚生労働科学研究費補助金 (難治性疾患政策研究事業). 食欲中枢異常による難治性高度肥満症の実態調査. (代表研究者 : 龍野一郎).
 
2) Saiki A, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes. 29 (9), 2005, 1115-20.
 
3) Saito Y, et al. Effect of protein-sparing modified fasting on obese Japanese patients. J Clin Biochem Nutr. 2 (1), 1987, 91-100.
 
4) Saiki A, et al. Background characteristics and postoperative outcomes of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Japanese Survey of Morbid and Treatment-Resistant Obesity Group (J-SMART Group). Ann Gastroenterol Surg. 3 (6), 2019, 638-47.
 
5) 日本肥満症治療学会肥満外科治療ガイドライン策定委員会. 高度肥満症に対する安全で卓越した外科治療のためのガイドライン (2013年版). 2013, 13p.
 
6) Rosenberger PH, et al. Psychiatric disorder comorbidity and association with eating disorders in bariatric surgery. J Clin Psychiatry. 67 (7), 2006, 1080-5.
PubMed
7) Kalarchian NA, et al. Psychiatric disorders among bariatric surgery candidates : relationship to obesity and functional health status. Am J Psychiatry. 164 (2), 2007, 328-34.
 
8) 小山朝一ほか. ロールシャッハ・テストを用いた肥満症患者の性格特性分析. 肥満研究. 15 (1), 2009, 39-44.
Medical*Online
9) 林果林ほか. 肥満症患者の心理的側面の特徴 : ロールシャッハ変数の比較分析から. 心身医学. 56 (9), 2016, 920-30.
Medical*Online
10) 肥満症治療学会編. 肥満症治療に必須な心理的背景の把握と対応. 2016, 68p.
 
11) 安梅勅江. エンパワメントのケア科学―当事者主体のチームワーク・ケアの技法. 医歯薬出版, 2004, 136p.
 
12) Dayan PH, et al. A new clinical perspective : Treating obesity with nutritional coaching versus energy-restricted diets. Nutrition. 60, 2019, 147-51.
PubMed
P.8 掲載の参考文献
1) 日本肥満学会編. 肥満症診療ガイドライン 2016. ライフサイエンス出版, 2016, 巻頭図表.
 
2) 日本肥満学会肥満症診断基準検討委員会編. 肥満症診断基準 2011. 肥満研究. 17 (臨時増刊号), 2011.
 
3) Young T, et al. Risk factors for obstructive sleep apnea in adults. JAMA. 291 (16), 2004, 2013-6.
PubMed
4) Shamsuzzaman AS, et al. Obstructive sleep apnea : Implication for cardiac and vascular disease. JAMA. 290 (14), 2003, 1906-14.
PubMed
5) Chagnae A, et al. Obesity-induced glomerular hyperfiltration : its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 23 (12), 2008, 3946-52.
PubMed
6) Helal I, et al. Glomerula hyperfiltration : definitions, mechanisms and clinical implications. Nat Rev Nephrol. 8 (5), 2012, 293-300.
 
7) Hsu CY, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 144 (1), 2006, 21-8.
PubMed
8) Praga M, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 16 (9), 2001, 1790-8.
PubMed
9) Sadeghian G, et al. Evaluation of insulin resistance in obese women with and without acanthosis nigricans. J Dermatol. 36 (4), 2009, 209-12.
PubMed
10) Ice CL, et al. Metabolic syndrome in fifth grade children with acanthosis nigricans : results from the CARDIAC project. World J Pediatr. 5 (1), 2009, 23-30.
PubMed
P.12 掲載の参考文献
1) 日本肥満学会肥満症診断基準検討委員会. 新しい肥満の判定と肥満症の診断基準. 肥満研究. 6, 2000, 18-28.
Medical*Online
2) 日本肥満学会肥満症治療ガイドライン作成委員会. 肥満症治療ガイドライン 2006. 肥満研究. 12 (臨時増刊号), 2006.
 
3) 日本肥満学会肥満症診断基準検討委員会. 肥満症診断基準 2011. 肥満研究. 17 (臨時増刊号), 2011, 1-78.
 
4) 日本肥満学会編. 肥満症診療ガイドライン 2016. ライフサイエンス社, 2016, 132p
 
P.17 掲載の参考文献
1) Rajan TM, et al. Psychiatric disorders and obesity : a review of association studies. J Postgrad Med. 63 (3), 2017, 182-90.
PubMed
2) Darby A, et.al. The rising prevalence of comorbid obesity and eating disorder behaviors from 1995 to 2005. Int J Eat Diord. 42 (2), 2009, 104-8.
 
3) Luppino FS, et.al. Overweight, obesity, and depression. Arch Gen Psychiatry. 67 (3), 2010, 220-9.
PubMed
4) 功刀浩. 肥満と精神疾患. ホルモンと臨床. 63 (2), 2015, 133-7.
 
5) 日本肥満症治療学会メンタルヘルス部会編. 肥満症治療に必須な心理的背景の把握と対応. 2016, 13-5.
 
6) 林果林ほか. 高度肥満患者に併存する精神疾患 : うつ症状を中心に. 日本心療内科学会誌. 20 (4), 2016, 267-72.
 
7) Lutter M, et al. Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr. 139 (3), 2009, 629-32.
PubMed
8) Vander Wal JS. Night eating syndrome : a critical review of the literature. Clin Psychol Rev. 32 (1), 2012, 49-59.
PubMed
9) Charles S, et al. The psychology of obesity. Abdom Imaging. 37 (5), 2012, 733-7.
 
10) 八田耕太郎ほか. 日本総合病院精神医学会治療戦略検討委員会編. 向精神薬・身体疾患治療薬の相互作用に関する指針. 星和書店, 2011, 35-44, 61-8.
 
11) 四宮滋子ほか監訳. カプラン臨床精神医学テキスト 日本語版第3版, 井上令一監修. メディカル・サイエンス・インターナショナル, 2016, 1672p.
 
12) 桂川修一. 働き盛りのうつ病予防. 産業精神保健. 26 (特別号), 2018, 88-93.
 
13) 功刀浩. うつ病リスク因子としての食生活・栄養. 臨床精神医学. 44 (4), 2015, 513-9.
Medical*Online
14) 野崎剛弘ほか. 心療内科の立場から肥満を心療内科的に科学する. 糖尿病診療マスター. 12 (1), 2014, 57-60.
 
15) Mauri M, et al. Axis I and II disorders and quality of life in bariatric surgery candidates. J Clin Psychiatry. 69 (2), 2008, 295-301.
PubMed
P.22 掲載の参考文献
1) 日本糖尿病学会編著. "Q3-3 総エネルギー摂取量をどのように定めるか? ". 糖尿病診療ガイドライン 2019. 南江堂, 2019, 34-7.
 
2) "CQ14-6 高度肥満症を伴う2型糖尿病への外科療法は有効か? ". 糖尿病診療ガイドライン 2019. 南江堂, 2019, 236-8.
 
3) Ugi S, et al. Preserving β-cell function is the major determinant of diabetes remission following laparoscopic sleeve gastrectomy in Japanese obese diabetic patients. Endocr J. 66 (9), 2019, 817-26.
 
4) Saiki A, et al. Background characteristics and postoperative outcome of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Ann Gastroenterol Surg. 3 (6), 2019, 638-47.
PubMed
5) Dixon JB, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes : randomized controlled trial. JAMA. 299 (3), 2008, 316-23.
PubMed
6) Ikramuddin S, et al. Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. JAMA. 319 (3), 2018, 266-78.
PubMed
7) Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes-5-year outcomes. N Eng J Med. 376 (7), 2017, 641-51.
 
8) Courcoulas AP, et al. Bariatric Surgery vs lifestyle intervention for diabetes treatment : 5-year outcomes from a randomized trial. J Clin Endocrinol Metab. 105 (3), 2020, 866-76.
 
9) Sha Y, et al. Laparoscopic Roux-en-Y gastric bypass versus sleeve gastrectomy for type 2 diabetes mellitus in nonseverely obese patients : a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 30 (5), 2020, 1660-70.
PubMed
10) Wang L, et al. Effect of laparoscopic sleeve gastrectomy on type 2 diabetes mellitus in patients with body mass index less than 30 kg/m2. Obes Surg. 29 (3), 2019, 835-42.
PubMed
11) Aminian A, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 322 (13), 2019, 1271-82.
PubMed
12) Yan G, et al. Long-term outcomes of macrovascular diseases and metabolic indicators of bariatric patients with a meta-analysis. PLoS One. 14 (12), 2019, e0224828.
PubMed
13) Khera AV, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. Cell. 177 (3), 2019, 587-96.
PubMed
P.26 掲載の参考文献
1) 厚生労働省. 平成30年国民健康・栄養調査結果の概要.
 
2) 日本肥満症治療学会治療メンタル部会. 肥満症治療に必須な心理的背景の把握と対応 : 内科的・外科的治療の効果を上げるために. 2016.
 
3) 日本肥満症治療学会治療ガイドライン委員会. 肥満症の総合的治療ガイド. 2013.
 
4) Saiki A, et al. Background characteristics and postoperative outcomes of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Ann Gastroenterol Surg. 3 (6), 2019, 638-47.
PubMed
5) The 2nd Diabetes Surgery Summit (DSS-II) : an International Consensus Conference, London, UK, 2017.
 
6) 5th IFSO Global Registry Report 2019.
 
7) Flum DR, et al. Impact of gastric bypass operation on survival : a population-based analysis. J Am Coll Surg. 199 (4), 2004, 543-51.
PubMed
8) Flum DR, et al. Bariatric Obesity Outcome Modeling Collaborative. Ann Surg. 254 (6), 2011, 860-5.
PubMed
P.30 掲載の参考文献
1) 厚生労働省. 平成30年 国民健康・栄養調査報告.
 
2) 厚生労働省. 平成29年 人口動態統計.
 
3) 厚生労働省. 平成29年度 国民医療費の概況.
Medical*Online
4) Rubino F, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes : a Joint Statement by International Diabetes Organizations. Obes Surg. 27 (1), 2017, 2-21.
PubMed
5) Surbhi Gupta. "Emerging interest of Big Pharma in obesity : Will the market for prescription antiobesity drugs see a new light?" Decision Resources Group. 2017. https://decisionresourcesgroup.com/blog/emerginginterest-big-pharma-obesity-will-market-prescriptionantiobesity-drugs-see-new-light (2020.1.31参照)
 
6) 日本肥満症治療学会肥満外科治療ガイドライン策定委員会. 日本における高度肥満症に対する安全で卓越した外科治療のためのガイドライン (2013年版). 2013, 13p. http://plaza.umin.ne.jp/~jsto/gakujyutsu/updata/surgery_guideline_2013.pdf (2020.1.31参照)
 
7) 5th IFSO Global Registry Report 2019. https://www.ifso.com/pdf/5th-ifso-global-registry-reportseptember-2019.pdf (2020.1.31参照)
 

第2章 高度肥満症に対する外科治療前の管理

P.38 掲載の参考文献
1) Sogg S, et al. The Boston interview for gastric bypass : determining the psychological suitability of surgical candidates. Obes Surg. 14 (3), 2004, 370-80.
PubMed
2) 齋藤康ほか. 肥満症治療のためのフォーミュラ食療法 : 原理と実践. ウェートコントロール普及協会, 2007, 28-43.
 
3) Shirai K, et al. The effects of partial use of formula diet on weight reduction and metabolic variables in obese type 2 diabetic patients--multicenter trial. Obes Res Clin Pract. 7 (1), 2013, e43-54.
PubMed
4) Saiki A, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes. 29 (9), 2005, 1115-20.
 
5) 齋木厚人ほか. フォーミュラ食1食置き換えによる肥満外科治療後の栄養学的フォローアップ (術後12カ月間の検討). 日本栄養学会雑誌. 36 (2), 2014, 112-8.
 
6) Faria SL, et al. Dietary protein intake and bariatric surgery patients : a review. Obes surg. 21 (11), 2011, 1798-805.
PubMed
7) 金居理恵子ほか. 肥満外科治療後のフォーミュラ食が, 著明な体脂肪減少と骨格筋量の維持に寄与しえた1例. 日本臨床栄養学会雑誌. 38 (2), 2016, 97-103.
Medical*Online
8) 小山朝一ほか. ロールシャッハ・テストを用いた肥満症患者の性格特性分析 ハイラムダスタイルについて. 肥満研究. 15 (1), 2009, 39-44.
Medical*Online
9) Saiki A, et al. Background characteristics and postoperative outcomes of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Ann Gastroenterol Surg. 3 (6), 2019, 638-47.
PubMed
10) Safety Committee of Japanese Society of Anesthesiologists. A guideline for perioperative smoking cessation. J Anesth. 31 (2), 2017, 297-303.
PubMed
P.43 掲載の参考文献
1) Takahashi H, et al. TGF-β2 is an exercise-induced adipokine that regulates glucose and fatty acid metabolism. Nat Metab. 1 (2), 2019, 291-303.
 
2) Dewal RS, Stanford KI. Effects of exercise on brown and beige adipocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 1864 (1), 2019, 71-8.
 
3) Fukushima Y, et al. Effects of Body Weight Reduction on Serum Irisin and Metabolic Parameters in Obese Subjects. Diabetes Metab J. 40 (5), 2016, 386-95.
PubMed
4) Kamo T, et al. Epigenetic mechanism controls PDK4 gene activation before and after exercise therapy following artificial knee arthroplasty. Clin Interv Aging. 14, 2019, 1433-43.
PubMed
5) Fujikawa T, et al. The hypothalamic regulation of metabolic adaptations to exercise. J Neuroendocrinol. 29 (10), 2017, 1-11.
 
6) Shinno H, et al. Evaluation of a static stretching intervention on vascular endothelial function and arterial stiffness. Eur J Sport Sci. 17 (5), 2017, 586-92.
PubMed
7) 木村穣. 運動プログラムの効果と実際 : 動脈硬化における運動療法の臨床的検討. 臨床スポーツ医学. 28 (12), 2011, 1365-70.
Medical*Online
8) Ravussin E. Physiology. A NEAT Way to Control Weight? Science. 307 (5709), 2005, 530-1.
PubMed
9) 木村穣. 心臓リハビリテーションにおけるイノベーション. 循環器内科. 86 (5), 2019, 623-8.
 
10) 木村穣. 肥満症治療チームに必要な行動変容理論と各構成要員の役割. 肥満研究. 18 (2), 2012, 78-84.
Medical*Online
11) 福島八枝子ほか. 減量成功の女性肥満患者におけるインスリン抵抗性と体組成因子の検討. 肥満研究. 22 (3), 2016, 207-12.
Medical*Online
P.47 掲載の参考文献
1) Nishikawa T, et al. Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy. Endocr J. 43 (6), 1996, 671-7.
PubMed
2) Suplicy H, et al. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes. 38 (8), 2014, 1097-103.
 
3) Wigal TL, et al. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). CNS Drugs. 32 (3), 2018, 289-301.
PubMed
4) Hioki C, et al. Efficacy of Bofu-tsusho-san, an oriental herbal medicine, in obese Japanese women with impaired glucose tolerance. Clinical and Experimental Pharmacology and Physiology. 31 (9), 2004, 614-9.
PubMed
5) Azushima K, et al. Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension : A multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2). Atherosclerosis. 240 (1), 2015, 297-304.
PubMed
6) Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 375 (4), 2016, 311-22.
PubMed
7) Astrup A, et al. Effects of liraglutide in the treatment of obesity : a randomised, double-blind, placebo-controlled study. The Lancet. 374 (9701), 2009, 1606-16.
 
8) Astrup A, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 36 (6), 2012, 843-54.
PubMed
9) O'Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity : a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 392 (10148), 2018, 637-49.
 
10) Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 375 (19), 2016, 1834-44.
 
11) Pereira MJ, et al. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 79 (3), 2019, 219-30.
PubMed
12) McElroy SL, et al. Topiramate for the treatment of binge eating disorder associated with obesity : a placebo-controlled study. Biol Psychiatry. 61 (9), 2007, 1039-48.
PubMed
13) Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis. The Lancet. 382 (9896), 2013, 951-62.
 
P.50 掲載の参考文献
1) 吉松博信. 肥満症の行動療法. 別冊・医学のあゆみ : 糖尿病・代謝症候群. 2004, 827-34.
 
2) 正木孝幸ほか. 肥満の治療 : 行動療法・心理療法・チーム医療. 内科. 117 (1), 2016, 79-82.
 
3) 正木孝幸. 高度肥満症の診断基準と治療アプローチ. The Lipid. 28 (4), 2017, 374-8.
Medical*Online
P.56 掲載の参考文献
1) Dawes AJ, et al. Mental health conditions among patients seeking and undergoing bariatric surgery A Meta-analysis. JAMA. 315 (2), 2016, 150-63.
PubMed
2) Poole NA, et al. Compliance with surgical after-care following bariatric surgery for morbid obesity : a retrospective study. Obes Surg. 15 (2), 2005, 261-5.
PubMed
3) National Heart, Lung, and Blood Institute Obesity Education Initiative. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults : The Evidence Report. NIH Publication No. 98-4083. Bethesda, MD ; U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute ; 1998.
 
4) 野崎剛弘ほか. 肥満の認知行動療法 : ライフスタイル改善のための心身医学的アプローチ. 福岡医学誌. 105 (7), 2014, 139-47.
 
5) Paul L, et al. Does cognitive behavioral therapy strengthen the effect of bariatric surgery for obesity? Design and methods of a randomized and controlled study. Contemp Clin Trials. 42, 2015, 252-6.
PubMed
6) Gade H, et al. The Impact of a preoperative cognitive behavioural therapy (CBT) on dysfunctional eating behaviours, affective symptoms and body weight 1 year after bariatric surgery : a randomized controlled trial. Obes Surg. 25 (11), 2015, 2112-9.
PubMed
7) Ashton K, et al. Positive response to binge eating intervention enhances postoperative weight loss. Surg Obes Relat Dis. 7 (3), 2011, 315-20.
PubMed
8) Rudolph A, et al. Post-operative behavioural management in bariatric surgery : a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 14 (4), 2013, 292-302.
PubMed
9) Weineland S, et al. Psychological flexibility and the gains of acceptance-based treatment for post-bariatric surgery : six-month follow-up and a test of the underlying model. Clin Obes. 2 (1-2), 2012, 15-24.
 
10) Himes SM, et al. Stop Regain : A pilot psychological intervention for bariatric patients experiencing weight regain. Obes Surg. 25 (5), 2015, 922-7.
PubMed
P.61 掲載の参考文献
1) Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 518 (7538), 2015, 197-206.
PubMed
2) Tomiyama AJ, et al. How and why weight stigma drives the obesity 'epidemic' and harms health. BMC Med. 16 (1), 2018, 123.
PubMed
3) Swencionis C, et al. The psychology of obesity. Abdom Imaging. 37 (5), 2012, 733-7.
PubMed
4) Sogg S, et al. Psychosocial Evaluation for Bariatric Surgery : The Boston Interview and Opportunities for Intervention. Obes Surg. 19 (3), 2009, 369-77.
 
5) Kalarchian MA, et al. Psychiatric disorders among bariatric surgery candidates : relationship to obesity and functional health status. Am J Psychiatry. 164 (2), 2007, 328-34.
PubMed
6) 林果林ほか. 肥満症患者の心理的側面の特徴 : ロールシャッハ変数の比較分析から. 心身医学. 56 (9), 2016, 920-30.
Medical*Online
7) Yu ZB, et al. Intelligence in relation to obesity : a systematic review and meta-analysis. Obes Rev. 11 (9), 2010, 656-70.
PubMed
8) Zheng Z, et al. Association among obesity, overweight and autism spectrum disorder : a systematic review and meta-analysis. Sci Rep. 7 (1), 2017, 11697.
PubMed
9) Luppino FS, et al. Overweight, Obesity, and Depression. A systematic Review and Meta-analysis of Longitudinal Studies. Arch Gen Psychiatry. 67 (3), 2010, 220-9.
PubMed
10) Saiki A, et al. Background characteristics and postoperative outcomes of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Ann Gastroenterol Surg. 3 (6), 2019, 638-47.
PubMed
P.65 掲載の参考文献
1) Bruce JB, et al. How do we define cure of diabetes? Diabet Care. 32 (11), 2009, 2133-5.
 
2) Lee WJ, et al. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus : predicting the success by ABCD score. Surg Obes Relat Dis. 11 (5), 2015, 991-6.
PubMed
3) Still CD, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery : a retrospective cohort study. Lancet Diabetes Endocrinol. 2 (1), 2014, 38-45.
PubMed
4) Aminian A, et al. Individualized Metabolic Surgery Score : Procedure Selection Based on Diabetes Severity. Ann Surg. 266 (4), 2017, 650-7.
PubMed
5) Hansel B, et al. Severe Chronic Kidney Disease Is Associated with a Lower Efficiency of Bariatric Surgery. Obesity Surgery. 29 (5), 2019, 1514-20.
PubMed
6) Turgeon NA, et al. The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol. 23 (5), 2013, 885-94.
 
7) Sjostrom L, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 311 (22), 2014, 2297-304.
PubMed
8) Murphy R, et al. Progression of diabetic retinopathy after bariatric surgery. Diabet Med. 32 (9), 2015, 1212-20.
PubMed
9) Busetto L, et al. Timing of bariatric surgery in people with obesity and diabetes. Ann Transl Med. 3 (7), 2015, 94.
PubMed
10) Mechanick JI, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures-2019 Update : Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Obesity (Silver Spring). 28 (4), 2020, O1-O58.
 
11) 日本糖尿病学会 編・著. 糖尿病専門医研修ガイドブック (改訂第7版). 診断と治療社, 2017, 388.
 
12) 日本糖尿病学会. メトホルミンの適正使用に関するRecommendation. 2020年3月18日改訂. http://www.fa.kyorin.co.jp/jds/uploads/recommendation_metformin.pdf (2020.4.9参照)
 
13) Andalib A, et al. Diabetic Ketoacidosis Following Bariatric Surgery in Patients with Type 2 Diabetes. Diabetes Care. 39 (8), 2019, e121-2.
 
P.71 掲載の参考文献
1) Chung F, et al. Society of Anesthesia and Sleep Medicine Guidelines on Preoperative Screening and Assessment of Adult Patients With Obstructive Sleep Apnea. Anesth Analg. 123 (2), 2016, 452-73.
PubMed
2) ASMBS Clinical Issues Committee. Peri-operative management of obstructive sleep apnea. Surg Obes Relat Dis. 8 (3), 2012, e27-32.
PubMed
3) Hallowell PT, et al. Potentially life-threatening sleep apnea is unrecognized without aggressive evaluation. Am J Surg. 193 (3), 2007, 364-7.
PubMed
4) Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg. 13 (5), 2003, 676-83.
PubMed
5) Chung F, et al. STOP questionnaire : a tool to screen patients for obstructive sleep apnea. Anesthesiology. 108 (5), 2008, 812-21.
PubMed
6) Chung F, et al. STOP-Bang questionnaire : a practical approach to screen for obstructive sleep apnea. Chest. 149 (5), 2016, 631-38.
PubMed
7) Seet E, et al. High STOP-BANG questionnaire scores predict intraoperative and early postoperative adverse events. Singapore Med J. 56 (4), 2015, 212-6.
PubMed
8) Vasu TS, et al. Obstructive sleep apnea syndrome and postoperative complications : clinical use of the STOPBANG questionnaire. Arch Otolaryngol Head Neck Surg. 136 (10), 2010, 1020-4.
PubMed
9) Ramachandran SK, et al. Postoperative Respiratory Complications in Patients at Risk for Obstructive Sleep Apnea : A Single-Institution Cohort Study. Anesth Analg. 125 (1), 2017, 272-9.
PubMed
10) Netzer NC, et al. Using the Berlin questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 131 (7), 1999, 485-91.
PubMed
11) Shafer A. Anesthesia Checklist. Anesthesiology 116 (2), 2012, 477-8.
 
12) Collop NA, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 15 (3), 2007, 737-47.
 
13) Abdelsattar ZM, et al. The impact of untreated obstructive sleep apnea on cardiopulmonary complications in general and vascular surgery : a cohort study. Sleep. 38 (8), 2015, 1205-10.
PubMed
14) Nagappa M, et al. The effects of continuous positive airway pressure on postoperative outcomes in obstructive sleep apnea patients undergoing surgery : a systematic review and meta-analysis. Anesth Analg. 120 (5), 2015, 1013-23.
PubMed
15) Young LR, et al. Response to CPAP withdrawal in patients with mild versus severe obstructive sleep apnea/hypopnea syndrome. Sleep. 36 (3), 2013, 405-12.
PubMed

第3章 メタボリックサージェリーの実際

P.78 掲載の参考文献
1) チーム医療推進協議会. チーム医療とは. https://www.team-med.jp (2020.2.2参照)
 
2) チーム医療推進協議会. チーム医療の定義と理念. http://www.team-med.jp/philosophy (2020.2.2参照)
 
3) 日本肥満症治療学会. 日本における高度肥満症に対する安全で卓越した外科治療のためのガイドライン (2013年版). 2013, 13p.
 
4) 日本肥満症治療学会ホームページ. http://plaza.umin.ne.jp/~jsto/gekashisetsu/ninteishinsa2019.html (2020.2.2参照)
 
5) Schiavo L, et al. A 4-Week Preoperative Ketogenic Micronutrient-Enriched Diet Is Effective in Reducing Body Weight, Left Hepatic Lobe Volume, and Micronutrient Deficiencies in Patients Undergoing Bariatric Surgery : a Prospective Pilot Study. Obes Surg. 28 (8), 2018, 2215-24.
PubMed
6) 西山純一. 手術体位による合併症 : 末梢神経障害を中心に. 日本臨床麻酔学会誌. 37 (2), 2017, 2019.
 
P.82 掲載の参考文献
1) Rubino F, et al. Metabolic Surgery in the Treatment Algorithm for Type2 Diabetes : A Joint Statement by International Diabetes Organizations. Diabetes Care. 39 (6), 2016, 861-77.
 
2) 日本糖尿病学会編. 糖尿病診療ガイドライン 2019. 南江堂, 236-8.
 
3) Peters AL, et al. Euglycemic diabetic ketoacidosis : a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 38 (9), 2015, 1687-93.
PubMed
4) 日本肥満学会編. 肥満症治療ガイドライン 2016. ライフサイエンス出版, 57-8.
 
5) Muramoto A, et al. Three percent weight reduction in the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 8 (5), 2014, e466-75.
PubMed
P.88 掲載の参考文献
1) Hubbard VS, et al. Gastrointestinal Surgery for Severe Obesity. Obes Surg. 1 (3), 1991, 257-65.
PubMed
2) 中里哲也ほか. チーム医療とコメディカルの役割 : 肥満外科のチーム医療とは? : 肥満外科のチーム医療について教えてください. Q&Aでわかる肥満と糖尿病. 10 (5), 2011, 682- 4.
 
3) 園田和子ほか. 肥満症 (第2版) : 基礎・臨床研究の進歩 : 肥満症のフォローアップシステム : チーム医療 : 肥満症診療におけるチーム医療の重要性と構成要員 : 看護師の役割. 日本臨床. 68 (増刊号 2), 2010, 723-6.
 
4) 伊波早苗. 肥満症治療 : 肥満症に対する集学的治療 : 肥満症手術を受ける患者の教育 : 看護師による術前術後の認知教育. ホルモンと臨床. 61 (2), 2013, 171-6.
 
5) 山口剛ほか. 高度肥満症に対する減量外科治療のためのチーム医療. 滋賀医科大学雑誌. 27 (1), 2014, 32-7.
 
6) 山口剛ほか. 減量外科チームによる腹腔鏡下スリーブ状胃切除術後の効果不良群の検討. 滋賀医科大学雑誌. 28 (1), 2015, 34-9.
 
7) 日本看護協会. 認定看護師. https://nintei.nurse.or.jp/nursing/qualification/cn (2020.1.28 閲覧)
 
8) 日本看護協会. 専門看護師. https://nintei.nurse.or.jp/nursing/qualification/cns (2020.1.28 閲覧)
 
9) Haslam DW, et al. Obesity. Lancet. 366 (9492), 2005, 1197-209.
PubMed
10) 山口剛ほか. 術後管理 : 肥満患者の術後管理 : 生理的変化と合併疾患, アウトカム, 術後管理のポイントとその実際 : 肥満による生理的変化と合併疾患. Intensivist. 4 (2), 2012, 365-69, 375-6.
 
11) 白石としえ. 術後管理 : 肥満患者の術後管理 : 生理的変化と合併疾患, アウトカム, 術後管理のポイントとその実際 : 肥満における術後管理のポイント. Intensivist. 4 (2), 2012, 371-4, 376-7.
 
12) Benumof JL, et al. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology. 87 (4), 1997, 979-82.
 
13) 白石としえ. 病的肥満の治療と麻酔 : 肥満外科手術の麻酔 : "Plan for the Worst, Hope for the Best!" 最悪を想定して計画を練り, 最善を希求する. LiSA, 18 (2), 2011, 122-9.
 
P.96 掲載の参考文献
1) Alpert MA, et al. Effects of obesity on cardiovascular hemodynamics, cardiac morphology, and ventricular function. Curr Obes Rep. 5 (4), 2016, 424-34.
PubMed
2) Wolk R, et al. Obesity, sleep apnea, and hypertension. Hypertension. 42 (6), 2003, 1067-74.
PubMed
3) Jones RL, et al. The effects of body mass index on lung volumes. Chest. 130 (3), 2006, 827-33.
PubMed
4) Benumof J, et al. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1mg/kg intravenous succinylcholine. Anesthesiology. 87 (4), 1997, 979-82.
 
5) Brodsky JB, et al. Morbid obesity and tracheal intubation. Anesth Analg. 94 (3), 2002, 732-6.
PubMed
6) (有) レプラコン. http://www.leprechaun-ltd.com/
 
7) Dixon BJ, et al. Preoxygenation is more effective in the 25° head-up position than in the supine position in severely obese patients. Anesthesiology. 102 (6), 2005, 1110-5.
 
8) Garcia RM, et al. The obesity supine sudden death syndrome in the perioperative Patient. Crit Care & Shock. 17 (4), 2014, 82-4.
 
9) Nimmagadda U, et al. Preoxygenation with tidal volume and Deep breathing techniques : the impact of duration of breathing and fresh gas flow. Anes Analg. 92 (5), 2001, 1337-41.
 
10) Wong DT, et al. High-flow nasal oxygen improves safe apnea time in morbidly obese patients undergoing general anesthesia : A randomized controlled trial. Anesth Analg. 129 (4), 2019, 1130-6.
PubMed
11) Lemmens HJ, et al. Estimating blood volume in obese and morbidly obese patients. Obes Surg. 16 (6), 2006, 773-6.
PubMed
12) Janmahasatian S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 44 (10), 2005, 1051-65.
PubMed
13) Servin F, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology. 78 (4), 1993, 657-65.
PubMed
14) Ingrande J, et al. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 105 Suppl 1, 2010, i16-23.
 
15) Pieracci FM, et al. Critical care of the bariatric patient. Crit Care Med. 34 (6), 2006, 1796-804.
PubMed
16) 成田浩江ほか. 肥満患者におけるデスフルラン麻酔の有用性の検討. 麻酔. 67 (10), 2018, 1050-4.
Medical*Online
P.99 掲載の参考文献
1) Angrisani L, et al. IFSO Worldwide Survey 2016 : Primary, Endoluminal, and Revisional Procedures. Obes Surg. 28 (12), 2018, 3783-94.
PubMed
2) Lee WJ, et al. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus : predicting the success by ABCD score. Surg Obes Relat Dis. 11 (5), 2015, 991-6.
PubMed
3) Chang SH, et al. The effectiveness and risks of bariatric surgery : an updated systematic review and meta-analysis, 2003-12. JAMA Surg 149 (3), 2014, 275-87.
PubMed
4) DeMaria EJ, et al. Obesity surgery mortality risk score : proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass. Surg Obes Relat Dis. 3 (2), 2007, 134-40.
PubMed
5) Puzziferri N, et al. Long-term follow-up after bariatric surgery : a systematic review. JAMA. 312 (9), 2014, 934-42.
PubMed
6) Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 370 (21), 2014, 2002-13.
PubMed
7) Chang SH, et al. The effectiveness and risks of bariatric surgery : an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 149 (3), 2014, 275-87.
PubMed
P.102 掲載の参考文献
1) 日本内視鏡下肥満・糖尿病外科研究会. 腹腔鏡下肥満外科手術と内視鏡的胃内バルーン留置術の第6回アンケート調査 結果報告. 2020.
 
2) Buchwald H, et al. Bariatric surgery : A systematic review and meta-analysis. JAMA. 292 (14), 2004, 1724-37.
PubMed
3) Regan JP, et al. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg. 13 (6), 2003, 861-4.
PubMed
4) Anderson B, et al. The impact of laparoscopic sleeve gastrectomy on plasma ghrelin levels : A systematic review. Obes Surg. 23 (9), 2013, 1476-80.
 
5) Brethauer SA, et al. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis. 5 (4), 2009, 469-75.
PubMed
6) Langer FB, et al. Conversion from sleeve gastrectomy to Roux-en-Y gastric bypass--indications and outcome. Obes Surg. 20 (7), 2010, 835-40.
PubMed
7) Almalki OM, et al. Roux-en-Y gastric bypass for the treatment of Asian type II diabetes. Ann Laparosc Endosc Surg. 2 (7), 2017, 113-20.
 
8) Kasama K, et al. Laparoscopic sleeve gastrectomy with duodenojejunal bypass : technique and preliminary results. Obes Surg. 19 (10), 2009, 1341-5.
 
P.110 掲載の参考文献
1) Mason EE, et al. Gastric bypass in obesity. Surg Clin-North Am. 47 (6), 1967, 1345-51.
PubMed
2) Wittgrove AC, et al. Laparoscopic Gastric Bypass, Rouxen-Y : Preliminary Report of Five Cases. Obes Surg. 4 (4), 1994, 353-7.
 
3) Rutledge R. The mini-gastric bypass : experience with the first 1,274 cases. Obes Surg. 11 (3), 2001, 276-80.
PubMed
4) Buchwald H, et al. Metabolic/Bariatric Surgery Worldwide 2011. Obes Surg. 23 (4), 2013, 427-36.
PubMed
5) Lee WJ, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus : a randomized controlled trial. Arch Surg. 146 (2), 2011, 143-8.
PubMed
6) 稲嶺進ほか. 病的肥満に対する腹腔鏡下Roux-Y胃バイパス術の手技. 手術. 61 (11), 2007, 1647-54.
 
7) 稲嶺進ほか. 病的肥満と2型糖尿病の治療としての腹腔鏡下Roux-Y胃バイパス術の手技. 手術. 68 (9), 2014, 1165-71.
 
8) Higa KD, et al. Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity Technique and Preliminary Results of Our First 400 Patients. Arch Surg. 135 (9), 2000, 1029-33.
PubMed
9) 笠間和典ほか. "外科治療の適応". 肥満症の総合的治療ガイド. 齋藤康ほか監修. 日本肥満症治療学会. 2013, 66-7.
 
P.116 掲載の参考文献
1) Buchwald H, et al. Bariatric surgery worldwide 2003. Obes Surg. 14 (9), 2004, 1157-64.
PubMed
2) Buchwald H, et al. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 19 (12), 2009, 1605-11.
 
3) Angrisani L, et al. IFSO worldwide survey 2016 : Primary, endoluminal, and revisional procedures. Obes Surg. 28 (12), 2018, 3783-94.
PubMed
4) Bhandari M, et al. Standardization of bariatric metabolic procedures : World consensus Meeting statement. Obes Surg. 29 (Suppl 4), 2019, 5309-45.
 
5) Sabeti N, et al. Primary midline peritoneal access with optical trocar is safe and effective in morbidly obese patients. Surg Obes Relat Dis. 5 (5), 2009, 610-4.
PubMed
6) Gagner M, et al. The Second International Consensus Summit for Sleeve Gastrectomy, March 19-21, 2009. Surg Obes Relat Dis. 5 (4), 2009, 476-85.
 
7) 太田正之ほか. 腹腔鏡下肥満外科手術のピットフォールと対策. 外科. 76 (12), 2014, 1390-4.
 
8) Gagner M, et al. Survey on laparoscopic sleeve gastrectomy (LSG) at the Fourth International Consensus Summit on Sleeve Gastrectomy. Obes Surg. 23 (12), 2013, 2013-7.
PubMed
9) 太田正之ほか. 腹腔鏡下スリーブ状胃切除術. 消化器外科. 36 (5), 2013, 647-53.
 
10) Gagner M, et al. Comparison of laparoscopic sleeve gastrectomy leak rates in five staple-line reinforcement options : A systematic review. Surg Endosc. 34 (1), 2020, 396-407.
PubMed
P.124 掲載の参考文献
1) Kasama K, et al. Laparoscopic sleeve gastrectomy with duodenojejunal bypass : technique and preliminary results. Obes Surg. 19 (10), 2009, 1341-5.
 
2) Lee WJ, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus : a randomized controlled trial. Arch Surg. 146 (2), 2011, 143-8.
PubMed
3) Lee WJ, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients : efficacy and change of insulin secretion. Surgery. 147 (5), 2010, 664-9.
PubMed
4) Rosenthal R, et al. Effect of sleeve gastrectomy on patients with diabetes mellitus. Surg Obes Relat Dis. 5 (4), 2009, 429-34.
PubMed
P.130 掲載の参考文献
1) Brethauer SA, et al. Systematic review on reoperative bariatric surgery : American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 10 (5), 2014, 952-72.
PubMed
2) Angrisani L, et al. IFSO Worldwide Survey 2016 : Primary, Endoluminal, and Revisional Procedures. Obes Surg. 28 (12), 2018, 3783-94.
PubMed
3) English WJ, et al. American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 16 (4), 2020, 457-63.
PubMed
4) Amiki M, et al. Revisional Bariatric Surgery for Insufficient Weight Loss and Gastroesophageal Reflux Disease : Our 12-Year Experience. Obes Surg. 30 (5), 2020, 1671-8.
PubMed
5) 日本内視鏡下肥満・糖尿病外科研究会. 腹腔鏡下肥満外科手術と内視鏡的胃内バルーン留置術の第6回アンケート調査 結果報告, 2020.
 
6) Cheung D, et al. Revisional bariatric surgery following failed primary laparoscopic sleeve gastrectomy : a systematic review. Obes Surg. 24 (10), 2014, 1757-63.
PubMed
7) Malinka T, et al. Three-year outcomes of revisional laparoscopic gastric bypass after failed laparoscopic sleeve gastrectomy : a case-matched analysis. Obes Surg. 27 (9), 2017, 2324-30.
PubMed
8) Casillas RA, et al. Revision of primary sleeve gastrectomy to Roux-en-Y gastric bypass : indications and outcomes from a high-volume center. Surg Obes Relat Dis. 12 (10), 2016, 1817-25.
PubMed
9) Chen JC, et al. Protein deficiency after gastric bypass : The role of common limb length in revision surgery. Surg Obes Relat Dis. 15 (3), 2019, 441-6.
PubMed
10) Nedelcu M, et al. Revised sleeve gastrectomy (re-sleeve). Surg Obes Relat Dis. 11 (6), 2015, 1282-8.
PubMed
11) De Angelis F, et al. Re-sleeve Gastrectomy 4 Years Later : Is It Still an Effective Revisional Option? Obes Surg. 28 (11), 2018, 3714-6.
PubMed
12) Dijkhorst PJ, et al. Failed Sleeve Gastrectomy : Single Anastomosis Duodenoileal Bypass or Roux-en-Y Gastric Bypass? A Multicenter Cohort Study. Obes Surg. 2 (12), 2018, 3834-42.
 
13) Jamal MH, et al. The safety and efficacy of one anastomosis gastric bypass as a revision for sleeve gastrectomy. Obes Surg. 30 (6), 2020, 2280-4.
PubMed
P.134 掲載の参考文献
1) Mechanick JI, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures-2019 Update : Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 16 (2), 2020, 175-247.
 
2) Thorell A, et al. Guidelines for Perioperative Care in Bariatric Surgery : Enhanced Recovery After Surgery (ERAS) Society Recommendations. World J Surg. 40 (9), 2016, 2065-83.
PubMed
3) Chung F, et al. STOP-Bang Questionnaire : A Practical Approach to Screen for Obstructive Sleep Apnea. Chest. 149 (3), 2016, 631-8.
PubMed
4) Edholm D, et al. Preoperative 4-week low-calorie diet reduces liver volume and intrahepatic fat, and facilitates laparoscopic gastric bypass in morbidly obese. Obes Surg. 21 (3), 2011, 345-50.
PubMed
5) Watanabe A, et al. Preoperative Weight Loss and Operative Outcome After Laparoscopic Sleeve Gastrectomy. Obes Surg. 27 (10), 2017, 2515-21.
PubMed
6) American Society for Metabolic and Bariatric Surgery. Clinical Pearls for Emergency Care of the Bariatric Surgery Patient. http://s3.amazonaws.com/publicASMBS/ASMBS_Store/ASMBS_ER_Poster9-20-10.pdf (2020.1.30参照)
 
7) Semler MW, et al. A Multicenter, Randomized Trial of Ramped Position vs Sniffing Position During Endotracheal Intubation of Critically Ill Adults. Chest. 152 (4), 2017, 712-22.
PubMed
8) Berrios-Torres SI, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 152 (8), 2017, 784-91.
PubMed
9) 伊藤正明ほか. 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018. https://js-phlebology.jp/wp/wp-content/uploads/2019/03/JCS2017_ito_h.pdf (2020.1.31参照)
 
10) Bartlett MA, et al. Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vasc Health Risk Manag. 11, 2015, 461-77.
PubMed
11) Huerta S, et al. Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-Y gastric bypass. J Gastrointest Surg. 6 (3), 2002, 354-8.
PubMed
P.139 掲載の参考文献
1) Parrott J, et al. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update : Micronutrients. Surg Obes Relat Dis. 13 (5), 2017, 727-41.
PubMed
2) 吉川絵梨ほか. 高度肥満症に対する外科治療 (腹腔鏡下ルーワイ胃バイパス術) 術後の栄養指標, 食事量の変化. 日本臨床栄養学会雑誌. 34 (1), 2012, 2-7.
 
3) 吉川絵梨ほか. 減量手術後の食事満足度と食品許容度の評価. 日本病態栄養学会雑誌. 19 (4), 2016, 415-22.
 
4) Mathes CM, et al. Food selection and taste change in humans after Roux-en-Y gastric bypass surgery : A direct-measures approach. Physiol Behav. 107 (4), 2012, 476-83.
PubMed
5) 吉川絵梨ほか. 減量手術後の食習慣が減量効果に与える影響についての検討. 日本臨床栄養学会雑誌. 41 (2), 2019, 128-34.
Medical*Online
6) Fanituch J, et al. Severe protein-calorie malnutrition after bariatric procedures. Obes Surg. 14 (2), 2004, 175-81.
 
7) Aasheim ET, et al. Vitamin status after bariatric surgery : a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr. 90 (1), 2009, 15-22.
PubMed
8) 日本肥満症治療学会ガイドライン委員会編. 肥満症の総合的治療ガイド. 2013, 81.
 
9) Lupoli R, et al. Bariatric surgery and long-term nutritional issues. World J Diabetes. 8 (11), 2017, 464-74.
PubMed
P.145 掲載の参考文献
1) Haruta H, et al. Long-Term Outcomes of Bariatric and Metabolic Surgery in Japan : Results of a Multi-Institutional Survey. Obes Surg. 27 (3), 2017, 754-62.
PubMed
2) Bartlett MA, et al. Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vasc Health Risk Manag. 11, 2015, 461-77.
PubMed
3) 中村真潮ほか. 静脈血栓塞栓症. 静脈血栓塞栓症予防ガイドライン. 医療機器学. 78 (11), 2008, 886-93.
Medical*Online
4) Oshiro T, et al. Percutaneous transesophageal gastrotubing for management of gastric leakage after sleeve gastrectomy. Obes Surg. 24 (9), 2014, 1576-80.
PubMed
5) Chour M, The early use of Roux limb as surgical treatment for proximal postsleeve gastrectomy leaks. Surg Obes Relat Dis. 10 (1), 2014, 106-10.
 
6) El Hassan E, et al. Single-stage operative management of laparoscopic sleeve gastrectomy leaks without endoscopic stent placement. Obes Surg. 23 (5), 2013, 722-6.
PubMed
7) Abd Ellatif ME, et al. Management Options for Twisted Gastric Tube after Laparoscopic Sleeve Gastrectomy. Obes Surg. 27 (9), 2017, 2404-9.
PubMed
8) Saber AA, et al. Intra-thoracic Sleeve Migration (ITSM) : an Underreported Phenomenon After Laparoscopic Sleeve Gastrectomy. Obes Surg. 27 (8), 2017, 1917-23.
PubMed
9) Himpens JM. "Strictures After Sleeve Gastrectomy". The Perfect Sleeve Gastrectomy. Gagner M, et al. eds. Springer, Cham, 2020, 325-35.
 
10) Vilallonga R, et al. Laparoscopic management of persistent strictures after laparoscopic sleeve gastrectomy. Obes Surg. 23 (10), 2013, 1655-61.
PubMed
11) Oor JE, et al. Laparoscopic sleeve gastrectomy and gastroesophageal reflux disease : a systematic review and meta-analysis. Am J Surg. 211 (1), 2016, 250-67.
PubMed
P.150 掲載の参考文献
1) Lin HY, et al. Psychiatric disorders of patients seeking obesity treatment. BMC Psychiatry. 13, 2013, 1.
PubMed
2) Duarte-Guerra LS, et al. Psychiatric Disorders Among Obese Patients Seeking Bariatric Surgery : Results of Structured Clinical Interviews. Obes Surg. 25 (5), 2015, 830-7.
PubMed
3) Ishizuka M, et al. for the Japan Work Stress and Health Cohort Study Group. Influence of job strain on changes in body mass index and waist circumference--6-year longitudinal study. Scand J Work Environ Health. 34 (4), 2008, 288-96.
 
4) 肥満治療学会. "第4章 治療と管理・指導". 肥満治療ガイドライン 2016. ライフサイエンス出版. 2016, 38-70.
 
5) Fabricatore AN, et al. How Do Mental Health Professionals Evaluate Candidates for Bariatric Surgery? Survey Results. Obes Surg. 16 (5), 2006, 567-73.
PubMed
6) Jalilvand A, et al. Baseline psychiatric diagnoses are associated with early readmissions and long hospital length of stay after bariatric surgery. Surg Endosc. 33 (5), 2019, 1661-6.
PubMed
7) Dawes AJ, et al. Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery : A Meta-analysis. JAMA. 315 (2), 2016, 150-63.
PubMed
8) Burgmer R, et al. Psychological Outcome Two Years after Restrictive Bariatric Surgery. Obes Surg. 17 (6) 2007, 785-91.
PubMed
9) Morgan DJR, et al. Incidence and Determinants of Mental Health Service Use After Bariatric Surgery. JAMA Psychiatry. 77 (1), 2019, 60-7.
PubMed
10) Bhatti JA, et al. Self-harm Emergencies After Bariatric Surgery : A Population-Based Cohort Study. JAMA Surg. 151 (3), 2016, 226-32.
PubMed
P.154 掲載の参考文献
1) Nakazato T, et al. "Patient/Family Support Groups in Japan : A Model to Ensure the Success of Bariatric Surgery." Bariatric Times. March 2009.
 
2) 日本肥満症治療学会肥満外科治療ガイドライン策定委員会. 日本における高度肥満症に対する安全で卓越した外科治療のためのガイドライン (2013年版). 日本肥満症治療学会. 2013.
 
3) 黒木保博ほか. グループワークの専門技術-対人援助のための77の方法. 中央法規出版. 2001, 276p.
 
4) 保田井進ほか. 福祉グループワークの理論と実際. ミネルヴァ書房, 1999, 288p.
 
5) ASMBS ALLIED HEALTH SUPPORT GROUP COMMITEE, SUPPORT GROUP MANUAL.
 
6) 中里哲也. "患者サポートグループの重要性". 肥満・糖尿病の外科治療 : 手術テクニックからチーム医療の実際まで/Web手術動画つき. メディカ出版, 2017, 177-80.
 
P.157 掲載の参考文献
1) Angrisani L, et al. IFSO Worldwide Survey 2016 : Primary, Endoluminal, and Revisional Procedures. Obes Surg. 28 (12), 2018, 3783-94.
PubMed
2) Saiki A, et al. Background characteristics and postoperative outcomes of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Ann Gastroenterol Surg. 3 (6), 2019, 638-47.
PubMed
3) Hall KD, et al. Obesity Energetics : Body Weight Regulation and the Effects of Diet Composition. Gastroenterology. 152 (7), 2017, 1718-27.
PubMed
4) Emile SH, et al. Laparoscopic Sleeve Gastrectomy Then and Now : An Updated Systematic Review of the Progress and Short-term Outcomes Over the Last 5 Years. Surg Laparosc Endosc Percutan Tech. 27 (5), 2017, 307-17.
PubMed
5) Yu Y, et al. Predictors of weight regain after sleeve gastrectomy : an integrative review. Surg Obes Relat Dis. 15 (6), 2019, 995-1005.
PubMed
6) Noah J, et al. The sleeve gastrectomy and how and why it can fail? Surgery Curr Res. 4 (3), 2014, 1-3.
 
7) Nedelcu M, et al. Revised sleeve gastrectomy (re-sleeve). Surg Obes Relat Dis. 11 (6), 2015, 1282-8.
PubMed
8) 吉松博信. 肥満症の行動療法. 日本内科学会雑誌. 100 (4), 2011, 917-27.
 
9) Johnston BC, et al. Comparison of weight loss among named diet programs in overweight and obese adults : a meta-analysis. JAMA. 312 (9), 2014, 923-33.
PubMed
10) 齋木厚人ほか. フォーミュラ食の1食置き換えによる肥満外科治療後の栄養学的フォローアップ (術後12カ月間の検討). 日本臨床栄養学会雑誌. 36 (2), 2014, 112-8.
Medical*Online
11) Abiles V, et al. Psychological characteristics of morbidly obese candidates for bariatric surgery. Obes Surg. 20 (2), 2010, 161-7.
PubMed
12) Luppino FS, et al. Overweight, obesity, and depression : a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 67 (3), 2010, 220-9.
PubMed
13) de Zwaan M, et al. Anxiety and depression in bariatric surgery patients : a prospective, follow-up study using structured clinical interviews. J Affect Disord. 133 (1-2), 2011, 61-8.
 
14) Schwartz TL, et al. Psychiatric medication-induced obesity : A review. Obes Rev. 5 (2), 2004, 115-21
 
P.162 掲載の参考文献
1) 辻内琢也. メタボリックシンドローム言説の社会的危険性 [第2報]. 心身医学. 52 (10), 2012, 927-36.
Medical*Online
2) 斎藤康ほか監修. "日本における高度肥満症に対する安全で卓越した外科治療のためのガイドライン (2013年版)". 肥満症の総合的治療ガイド. 日本肥満症治療学会治療ガイドライン委員会編. 日本肥満症治療学会コンパス出版局, 2013, 巻末 IV.
 
P.166 掲載の参考文献
1) Livingston EH. The incidence of bariatric surgery has plateaued in the U. S. Am J Surg. 200 (3), 2010, 378-85.
 
2) 日本内視鏡下肥満・糖尿病外科研究会事務局. 腹腔鏡下肥満外科手術アンケート調査結果報告. 腹腔鏡下肥満外科手術と内視鏡的胃内バルーン留置術の第6回アンケート調査結果報告. 日本内視鏡下肥満・糖尿病外科研究会. 2020, 1-5.
 
3) 日本肥満症治療学会. 日本における高度肥満症に対する安全で卓越した外科治療のためのガイドライン (2013年版). 肥満症の総合的治療ガイド. 齋藤康ほか監修. 2013, I-VIII.
 
4) Kasama K, et al. IFSO-APC Consensus statements 2011. Obes Surg. 22 (5), 2012, 677-84.
PubMed
5) Pratt GM, et al. The ASBS Bariatric Surgery Centers of Excellence program : a blueprint for quality improvement. Surg Obes Relat Dis. 2 (5), 2006, 497-503.
 
6) Rubino F, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes : A Joint Statement by International Diabetes Organizations. Diabetes Care. 39 (6), 2016, 861-77.
PubMed
7) American Diabetes Association. Standard of medical care in diabetes-2017 Abridged for primary care providers. Clin Diabetes. 35 (1), 2017, 5-26.
PubMed

第4章 メタボリックサージェリーの改善メカニズムと効果

P.172 掲載の参考文献
1) Rubino F, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes : A Joint Statement by International Diabetes Organizations. Diabetes Care. 39 (6), 2016, 861-77.
PubMed
2) Kindel TL, et al. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest Surg. 13 (10), 2009, 1762-72.
PubMed
3) Rubino F, et al. The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes. Ann Surg. 244 (5), 2006, 741-9.
PubMed
4) le Roux CW, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 243 (1), 2006, 108-14.
PubMed
5) Thaler JP, et al. Hormonal and Metabolic Mechanisms of Diabetes Remission after Gastrointestinal Surgery. Endocrinology. 150 (6), 2009, 2518-25.
PubMed
6) Ryan K, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 509 (7499), 2014, 183-8.
PubMed
7) Miyachi T, et al. Biliopancreatic limb plays an important role in metabolic improvement after duodenaljejunal bypass in a rat model of diabetes. Surgery. 159 (5), 2016, 1360-71.
 
8) Ise I, et al. Changes in Enterohepatic Circulation after Duodenal-Jejunal Bypass and Reabsorption of Bile Acids in the Bilio-Pancreatic Limb. Obes Surg. 29 (6), 2019, 1901-10.
PubMed
9) Herder C, et al. Adiponectin and bariatric surgery : associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study. Diabetes Care. 37 (5), 2014, 1401-9.
PubMed
10) Chen J, et al. Serum leptin levels are inversely correlated with omental gene expression of adiponectin and markedly decreased after gastric bypass surgery. Surg Endosc. 26 (5), 2012, 1476-80.
PubMed
11) Netto BD, et al. Roux-en-Y Gastric Bypass Decreases Pro-inflammatory and Thrombotic Biomarkers in Individuals with Extreme Obesity. Obes Surg. 25 (6), 2015, 1010-8.
PubMed
12) Tremaroli V, et al, Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metab. 22 (2), 2015, 228-38.
PubMed
13) Shimizu H, et al. Regulation of host energy metabolism by gut microbiota-derived short-chain fatty acids. Glycative Stress Res. 6 (3), 2019, 181-91
 
14) Ochner CN, et al. The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity. Physiol Behav. 100 (5), 2010, 549-59.
PubMed
15) Mithieux G. A novel function of intestinal gluconeogenesis : central signaling in glucose and energy homeostasis. Nutrition. 25 (9), 2009, 881-4.
PubMed
16) Mithieux G. Influence of diabetes surgery on a gutbrainliver axis regulating food intake and internal glucose production. Nutr Hosp. 28 (Suppl 2), 2013, 109-14.
 
P.176 掲載の参考文献
1) 日本肥満学会. 肥満症診療ガイドライン 2016. ライフサイエンス出版, 2016
 
2) Rubino F, et al. ; Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes : A Joint Statement by International Diabetes Organizations. Surg Obes Relat Dis. 12 (6), 2016, 1144-62.
PubMed
3) Dixon JB, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes : a randomized controlled trial. JAMA. 299 (3), 2008, 316-23.
PubMed
4) Wentworth JM, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people : a randomised controlled trial. Lancet Diabetes Endocrinol. 2 (7), 2014, 545-52.
PubMed
5) Mingrone G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes : 5 year follow-up of an open-label, singlecentre, randomised controlled trial. Lancet. 386 (9997), 2015, 964-73.
PubMed
6) Ikramuddin S, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study) : 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol. 3 (6), 2015, 413-22.
PubMed
7) Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes- 5-year outcomes. N Engl J Med. 376 (7), 2017, 641-51.
PubMed
8) Simonson DC, et al. Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3 years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management : The SLIMMT2D Study. Diabetes Care. 41 (4), 2018, 670-9.
PubMed
9) Courcoulas AP, et al. Bariatric surgery vs. lifestyle intervention for diabetes treatment : five year outcomes from a randomized trial. J Clin Endocrinol Metab. 105 (3), 2020, 866-76.
 
10) Haruta H, et al. Long-term outcomes of bariatric and metabolic surgery in Japan : Results of a multi-institutional survey. Obes Surg. 27 (3), 2017, 754-62.
PubMed
11) Naitoh T, et al. Efficacy of sleeve gastrectomy with duodenal-jejunal bypass for the treatment of obese severe diabetes patients in Japan : A retrospective multicenter study. Obes Surg. 28 (2), 2018, 497-505.
PubMed
12) Lee WJ, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery : a comparison of DiaRem scores and ABCD scores. Obes Surg. 26 (10), 2016, 2418-24.
PubMed
13) Chen JC, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery : a comparison of DiaRem Scores and ABCD Scores. Surg Obes Relat Dis. 14 (5), 2018, 640-5.
 
P.180 掲載の参考文献
1) Buse JB, et al. How do we define cure of diabetes? Diabetes Care. 32 (11), 2009, 2133-5.
PubMed
2) Emous M, et al. Long-term self-reported symptom prevalence of early and late dumping in a patient population after sleeve gastrectomy, primary, and revisional gastric bypass surgery. Surg Obes Relat Dis. 14 (8), 2018, 1173-81.
 
3) Ahmad A, et al. Prevalence of dumping syndrome after laparoscopic sleeve gastrectomy and comparison with laparoscopic Roux-en-Y gastric bypass. Obes Surg. 29 (5), 2019, 1506-13.
PubMed
4) Ceriello A. The post-prandial state and cardiovascular disease : relevance to diabetes mellitus. Diabetes Metab Res Rev. 16 (2), 2000, 125-32.
PubMed
5) Desouza CV, et al. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 33 (6), 2010, 1389-94.
PubMed
6) Kwon Y, et al. Anemia, iron and vitamin B12 deficiencies after sleeve gastrectomy compared to Roux-en-Y gastric bypass : a meta-analysis. Surg Obes Relat Dis. 10 (4), 2014, 589-97.
PubMed
P.184 掲載の参考文献
1) de Raaff C, et al. Perioperative management of obstructive sleep apnea in bariatric surgery : a consensus guideline. Surg Obes Relat Dis. 13 (7), 2017, 1095-109.
PubMed
2) Hudgel DW. Sleep apnea severity classification? revisited. SLEEP. 39 (5), 2016, 1165-6.
PubMed
3) Peppard PE, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 284 (23), 2000, 3015-21.
PubMed
4) Ong TH, et al. Simplifying STOP-BANG : use of a simple questionnaire to screen for OSA in an Asian population. Sleep Breath. 14 (4), 2010, 371-6.
 
5) Lettieri CJ, et al. Persistence of obstructive sleep apnea after surgical weight loss. J Clin Sleep Med. 4 (4), 2008, 333-8.
PubMed
6) Tuomilehto HP, et al. Lifestyle intervention with weight reduction : first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med. 179 (4), 2009, 320-7.
PubMed
P.189 掲載の参考文献
1) Iseki K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 65 (5), 2004, 1870-6.
 
2) Hsu CY, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 144 (1), 2006, 21-8.
PubMed
3) Hashimoto Y, et al. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 10 (4), 2015, 578-83.
PubMed
4) Morales E, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 41 (2), 2003, 319-27.
PubMed
5) Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med. 376 (7), 2017, 641-51.
PubMed
6) Mingrone G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes : 5-year follow-up of an open-label, singlecentre, randomised controlled trial. Lancet. 386 (9997), 2015, 964-73.
PubMed
7) Carlsson LMS, et al. The incidence of albuminuria after bariatric surgery and usual care in Swedish obese subjects (SOS) : a prospective controlled intervention trial. Int J Obes. 39 (1), 2015, 169-75.
 
8) Chang AR, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int. 90 (1), 2016, 164-71.
PubMed
9) Iman TH, et al. Estimated GFR before and after bariatric surgery in CKD. Am J Kidney Dis. 69 (3), 2017, 380-8.
 
10) Navarro-Diaz M, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients : long-term follow-up. J Am Soc Nephrol. 17 (12 Suppl 3), 2006, S213-7.
 
11) Bilha SC, et al. The Effects of Bariatric Surgery on Renal Outcomes : a Systematic Review and Metaanalysis. Obes Surg. 28 (12), 2018, 3815-33.
PubMed
12) Nasrallah MP, et al. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 33 (1), 2013, 54-65.
PubMed
13) Rutkowski JM, et al. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol. 24 (2), 2013, 268-82.
PubMed
14) Axelsson J, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 69 (3), 2006, 596-604.
 
15) Ix JH, et al. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease : the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 21 (3), 2010, 406-12.
PubMed
P.192 掲載の参考文献
1) 来野哲史ほか. 特集 : 激変する肝疾患の現状 : 非アルコール性脂肪肝炎 (NASH) の治療. 臨牀と研究. 95 (5), 2017, 552-8.
 
2) 日本肝臓学会編. "NAFLD の疫学". NASH・NAFLDの診療ガイド 2015. 文光堂, 2015, 8-13.
 
3) Sasaki A, et al. Bariatric surgery and non-alcoholic Fatty liver disease : current and potential future treatments. Front Endocrinol (Lausanne). 27 (5), 2014, 164.
 
4) 関洋介ほか. 特集 : NAFLD/NASH IV. NAFLD/NASHの治療学 外科療法 (減量手術). 日本臨牀. 77 (5), 2019, 868-73.
 
5) Sumida Y, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 46 (4), 2011, 257-68.
 
6) Shah AG, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatrol. 7 (10), 2009, 1004-12.
 
7) Angulo P, et al. The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45 (4), 2007, 846-54.
 
8) Nikai H, et al. Effects of Laparoscopic Sleeve Gastrectomy on Non-Alcoholic Steatohepatitis and Liver Fibrosis in Japanese Patients with Severe Obesity. Obes Surg. 30 (7), 2020, 2579-87
 
9) Endo Y, et al. Improvement of non‐alcoholic fatty liver disease after laparoscopic sleeve gastrectomy in Japanese obese patients. Ann Gastroenterol Surg. 3 (3), 2019, 285-90.
 
10) 橋本悦子ほか. NAFLD/NASHの疾患概念の変遷 : 問われるNASH診断の意義. 肝臓. 59 (2), 2018, 83-91.
 
11) Matteoni CA, et al. Nonalcoholic fatty liver disease : A spectrum of clinical and pathological severity. Gastroenterology. 116 (6), 1999, 1413-9.
PubMed
12) Brunt EM, et al. Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94 (9), 1999, 2467-74.
PubMed
13) Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41 (6), 2005, 1313-21.
PubMed
14) Bedossa P, et al. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 60 (2), 2014, 565-75.
PubMed
15) Seki Y, et al. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing baliatric surgery. J Gastroenterol. 51 (3), 2016, 281-9.
PubMed
16) 日本消化器病学会編. "治療 : Clinical Question 4-14 減量手術は高度肥満のNAFLD/NASH に有効か?". NAFLD/NASH診療ガイドライン 2014. 南江堂, 2014, 110.
 
P.196 掲載の参考文献
1) Gokdeniz T, et al. Relation of epicardial fat thickness and cardio-ankle vascular index to complexity of coronary artery disease in nondiabetic patients. Cardiology. 124 (1), 2013, 41-8.
PubMed
2) Kathryn A, et al. Prevalence, distribution, and risk factor correlates of high thoracic periaortic fat in the Framingham Heart Study. J Am Heart Assoc. 1 (6), 2012, e004200.
 
3) Iacobellis G, et al. Epicardial fat : from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol. 43 (12), 2011, 1651-4.
 
4) Yudkin JS, et al. "Vasocrine" signalling from perivascular fat : a mechanism linking insulin resistance to vascular disease. Lancet. 365 (9473), 2005, 1817-20.
PubMed
5) Kenchaiah S, et al. Obesity and the Risk of Heart Failure. N Engl J Med. 347 (5), 2002, 305-13.
PubMed
6) Anker SD, et al. Wasting as Independent Risk Factor for Mortality in Chronic Heart Failure. Lancet. 349 (9058), 1997, 1050-3.
PubMed
P.200 掲載の参考文献
1) 宮本泰斗ほか. 高度な肥満を合併した子宮体癌患者に対する術前減量入院の有効性. 産婦人科の進歩. 71 (2), 2019, 81-6.
Medical*Online
2) Gunderson CC, et al. The impact of obesity on surgical staging, complications, and survival with uterine cancer : a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 133 (1), 2014, 23-7.
PubMed
3) Zhang X, et al. Intentional weight loss, weight cycling, and endometrial cancer risk : A systematic review and meta-analysis. Int J Gynecol Cancer. 29 (9), 2019, 1361-71.
 
4) Thomson CA, et al. Diet quality and survival after ovarian cancer : results from the Women's Health Initiative. J Natl Cancer Inst. 106 (11), 2014, pii : dju314.
 
5) Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 359 (6371), 2018, 91-7.
PubMed
6) Vangay P, et al. US Immigration Westernizes the Human Gut Microbiome. Cell. 175 (4), 2018, 962-72.
PubMed
7) Takayama K, et al. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer. 24 (8), 2016, 3473-80.
PubMed
8) Nishioka N, et al. Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. J Clin Med. 8 (4), 2019, pii : E450.
 
9) Best D, et al. How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence. Hum Reprod Update. 23 (6), 2017, 681-705.
 
10) Ciangura C, et al. Clinical Practice Guidelines for Childbearing Female Candidates for Bariatric Surgery, Pregnancy, and Post-partum Management After Bariatric Surgery. Obes Surg. 29 (11), 2019, 3722-34.
PubMed
11) Falcone V, et al. Pregnancy after bariatric surgery : a narrative literature review and discussion of impact on pregnancy management and outcome. BMC Pregnancy Childbirth. 18 (1), 2018, 507.
PubMed
12) Grandfils S, et al. Impact of gestational weight gain on perinatal outcomes after a bariatric surgery. J Gynecol Obstet Hum Reprod. 48 (6), 2019, 401-5.
PubMed
13) Dolin CD, et al. Association between time interval from bariatric surgery to pregnancy and maternal weight outcomes. J Matern Fetal Neonatal Med. 2019, 1-7. [Epub ahead of print]
 
14) Shawe J, et al. Pregnancy after bariatric surgery : Consensus recommendations for periconception, antenatal and postnatal care. Obes Rev. 20 (11), 2019, 1507-22.
PubMed

第5章 肥満症研究とトピックス

P.206 掲載の参考文献
1) Hartstra AV, et al. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 38 (1), 2015, 159-65.
PubMed
2) Le Chatelier E, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 500 (7464), 2013, 541-6.
PubMed
3) Tolhurst G, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 61 (2), 2012, 364-71.
 
4) Kimura I, et al. The gut microbiota suppresses insulinmediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 4, 2013, 1829.
PubMed
5) Chambers ES, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 64 (11), 2015, 1744-54.
 
6) Ridaura VK, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 341 (6150), 2013, 1241214.
PubMed
7) Tagawa H, et al. Bile acid binding resin improves hepatic insulin sensitivity by reducing cholesterol but not triglyceride levels in the liver. Diabetes Res Clin Pract. 109 (1), 2015, 85-94.
 
8) Morimoto K, et al. Intestinal bile acid composition modulates prohormone convertase 1/3 (PC1/3) expression and consequent GLP-1 production in male mice. Endocrinology. 157 (3), 2016, 1071-81.
PubMed
9) Kusumoto Y, et al. Bile acid binding resin prevents fat accumulation through intestinal microbiota in high-fat diet-induced obesity in mice. Metabolism. 71, 2017, 1-6.
PubMed
10) Kawano Y, et al. Colonic Pro-inflammatory Macrophages Cause Insulin Resistance in an Intestinal Ccl2/Ccr2-Dependent Manner. Cell Metab. 24 (2), 2016, 295-310.
 
11) Anhe FF, et al. Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity. Nature Metabolism. 2 (3), 2020, 233-42.
PubMed
12) Dao MC, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity : relationship with gut microbiome richness and ecology. Gut. 65 (3), 2016, 426-36.
PubMed
13) Caesar R, et al. Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. Cell Metab. 22 (4), 2015, 658-69.
PubMed
14) Miyamoto J, et al. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nature Commun. 10 (1), 2019, 4007.
 
15) Miyamoto J, et al. Barley beta-glucan improves metabolic condition via short-chain fatty acids produced by gut microbial fermentation in high fat diet fed mice. PloS One. 13 (4), 2018, e0196579.
PubMed
16) Luijten J, et al. The Importance of the Microbiome in Bariatric Surgery : a Systematic Review. Obes Surg. 29 (7), 2019, 2338-49.
PubMed
17) Kikuchi R, et al. The impact of laparoscopic sleeve gastrectomy with duodenojejunal bypass on intestinal microbiota differs from that of laparoscopic sleeve gastrectomy in Japanese patients with obesity. Clin Drug Investig. 38 (6), 2018, 545-52.
PubMed
18) Nakatani H, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism. 58 (10), 2009, 1400-7.
PubMed
19) Aron-Wisnewsky J, et al. Major microbiota dysbiosis in severe obesity : fate after bariatric surgery. Gut. 68 (1), 2019, 70-82.
PubMed
20) Tremaroli V, et al. Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metab. 22 (2), 2015, 228-38.
PubMed
21) de Groot P, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut. 69 (3), 2020, 502-12.
PubMed
P.210 掲載の参考文献
1) Katagiri H, et al. Adiposity and Cardiovascular Disorders : Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals. Circ Res. 101 (6), 2007, 27-39.
 
2) Sandoval DA, et al. Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov. 8 (5), 2009, 386-98.
PubMed
3) Yamada T, et al. Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms : Neuronal involvement in food-intake regulation. Cell Metab. 3 (3), 2006, 223-29.
PubMed
4) Uno K, et al. Neuronal Pathway from the Liver Modulates Energy Expenditure and Systemic Insulin Sensitivity. Science. 312 (5780), 2006, 1656-59.
PubMed
5) Tsukita S, et al. Hepatic Glucokinase Modulates Obesity Predisposition by Regulating BAT Thermogenesis via Neural Signals. Cell Metab. 16 (6), 2012, 825-32.
PubMed
6) Suganami T, et al. Adipose tissue macrophages : their role in adipose tissue remodeling. J Leukoc Biol. 88 (1), 2010, 33-39.
PubMed
7) Cusi K. Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis : Pathophysiology and Clinical Implications. Gastroenterology. 142 (4), 2012, 711-25.
PubMed
8) Komiya C, et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One. 11 (3), 2016, e0151511.
PubMed
9) Shiba K, et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 8 (1), 2018, 2362.
 
10) Affinati AH, et al. Bariatric Surgery in the Treatment of Type 2 Diabetes. Curr Diab Rep. 19 (12), 2019, 156.
 
P.214 掲載の参考文献
1) 御簾博文. 2型糖尿病との関係 : ヘパトカインによる制御. 非アルコール性脂肪性肝疾患 (NAFLD) の臨床的意義. 日本内科学会雑誌. 105 (1), 2016, 25-30.
 
2) 御簾博文. ヘパトカイン分泌異常と糖尿病. 臓器連関による生体恒常性. 実験医学増刊. 37 (7), 2019, 136-40.
 
3) Misu H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 12 (5), 2010, 483-95.
PubMed
4) Oo SM, et al. Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population. Sci Rep. 8 (1), 2018, 16727.
 
5) Ishikura K, et al. Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells. Diabetologia. 57 (9), 2014, 1968-76.
PubMed
6) Chadani H, et al. Endogenous Selenoprotein P, a Liver-Derived Secretory Protein, Mediates Myocardial Ischemia/Reperfusion Injury in Mice. Int J Mol Sci. 19 (3), 2018, 878.
 
7) Mita Y, et al. Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models. Nat Commun. 8 (1), 2017, 1658.
PubMed
8) Misu H, et al. Deficiency of the hepatokine selenoprotein P increases responsiveness to exercise in mice through upregulation of reactive oxygen species and AMP-activated protein kinase in muscle. Nat Med. 23 (4), 2017, 508-16.
PubMed
9) Lan F, et al. LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. Diabetes. 63 (5), 2014, 1649-64.
PubMed
10) Chikamoto K, et al. Rapid response of the steatosis-sensing hepatokine LECT2 during diet-induced weight cycling in mice. Biochem Biophys Res Commun. 478 (3), 2016, 1310-6.
PubMed
P.218 掲載の参考文献
1) 国立研究開発法人国立がん研究センター 社会と健康研究センター 予防研究グループ. 科学的根拠に基づくがんリスク評価とがん予防ガイドライン提言に関する研究 : エビデンスの評価. 2017. https://epi.ncc.go.jp/can_prev/, https://epi.ncc.go.jp/cgibin/cms/public/index.cgi/nccepi/can_prev/outcome/index (2020.2.21参照)
 
2) World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer : a Global Perspective. https://www.wcrf.org/dietandcancer/summary-thirdexpert-report (2020.2.21参照)
 
3) Inoue M, et al. Diabetes Mellitus and the Risk of Cancer. Results from a Large-Scale Population-Based Cohort Study in Japan. Arch Intern Med. 166 (17), 2006, 1871-77.
PubMed
4) 春日雅人ほか. 糖尿病と癌に関する委員会報告. 糖尿病. 56 (6), 2013, 374-90.
 
5) Afsane B, et al. Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer : Rational and Progress. J Cell Biochem. 119 (3), 2018, 2460-69.
 
6) Gogg S, et al. Increased MAPK Activation and Impaired Insulin Signaling in Subcutaneous Microvascular Endothelial Cells in Type 2 Diabetes : The Role of Endothelin-1. Diabetes. 58 (10), 2009, 2238-45.
PubMed
7) Yi-Cheng C, et al. The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes : from Molecular Mechanism to Clinical Implication. Am J Transl Res. 2 (3), 2010, 316-31.
 
8) Goto A, et al. Plasma Adiponectin Levels, ADIPOQ Variants, and Incidence of Type 2 Diabetes : A Nested Case-control Study. Diabetes Res Clin Pract. 127, 2017, 254-64.
PubMed
9) Amitabha R, et al. The Potential Role of Leptin in Tumor Invasion and Metastasis. Cytokine Growth Factor Rev. 38, 2017, 80-97.
 
10) Wiggins T, et al. Cancer Risk Following Bariatric Surgery-Systematic Review and Meta- analysis of National Population- Based Cohort Studies. Obes Surg. 29 (3), 2019, 1031-9.
PubMed
P.221 掲載の参考文献
1) Flum DR, et al. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA. 294 (15), 2005, 1903-8.
PubMed
2) Dorman RB, et al. Bariatric surgery outcomes in the elderly : an ACS NSQIP study. J Gastrointest Surg. 16 (1), 2012, 35-44.
PubMed
3) Chow A, et al. Roux-en-Y Gastric Bypass in the Elderly : a Systematic Review. Obes Surg. 26 (3), 2016, 626-30.
PubMed
4) Quirante FP, et al. Is bariatric surgery safe in the elderly population? Surg Endosc. 31 (4), 2017, 1538-43.
PubMed
5) Koh CY, et al. Outcomes of Laparoscopic Bariatric Surgery in the Elderly Population. Am Surg. 84 (10), 2018, 1600-3.
PubMed
6) Nevo N, et al. Sleeve Gastrectomy in the Elderly. Obes Facts. 12 (5), 2019, 502-8.
PubMed
7) Chouillard E, et al. Changing the quality of life in old age bariatric patients. Cross-sectional study for 79 old age patients. Int J Surg. 54 (Pt A), 2018, 236-41.
 
8) Pechman DM, et al. Bariatric surgery in the elderly : outcomes analysis of patients over 70 using the ACS-NSQIP database. Surg Obes Relat Dis. 15 (11), 2019, 1923-32.
PubMed
P.225 掲載の参考文献
1) Hotamisligil GS. Inflammation, Metaflammation and Immunometabolic Disorders. Nature. 542 (7640), 2017, 177-85.
PubMed
2) Kozuka C, et al. Brown rice and its components, γ-oryzanol, attenuate the preference for high fat diet by decreasing hypothalamic endoplasmic reticulum stress in mice. Diabetes. 61 (12), 2012, 3084-93.
 
3) Kozuka C, et al. Impact of brown rice-specific γ-Oryzanol on epigenetic modulation of dopamine D2 receptor in brain striatum of high fat diet-induced obese mice. Diabetologia. 60 (8), 2017, 1502-11.
 
4) Masuzaki H, et al. Brown rice-specific γ-oryzanol as a promising prophylactic avenue to protect against diabetes mellitus and obesity in humans. J Diabetes Investig. 10 (1), 2019, 18-25.
 
5) Thaler JP, et al. Obesity Is associated with hypothalamic injury in rodents and humans. J Clin Invest. 122 (1), 2012, 153-62.
PubMed
6) Garcia-Caceres C, et al. Role of astrocytes, microglia, and tanycytes in brain control of systemic metabolism. Nat Neurosci. 22 (1), 2019, 7-14.
PubMed
7) Killgore WDS, et al. Physical exercise and brain responses to images of high-calorie food. Neuroreport. 24 (17), 2013, 962-7.
PubMed
8) Kozuka C, et al. γ-Oryzanol protects pancreatic β-cells against endoplasmic reticulum stress in male mice. Endocrinology. 156 (4), 2015, 1242-50.
 
9) Wang GJ, et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage. 39 (4), 2008, 1824-31.
PubMed
10) DiLeone RJ, et al. The drive to eat : comparisons and distinctions between mechanisms of food reward and drug addiction. Nat Neurosci. 15 (10), 2012, 1330-5.
PubMed
11) Ahmadian M, et al. ERRγ preserves brown fat innate thermogenic activity. Cell Rep. 22 (11), 2018, 2849-59.
 
12) 益崎裕章ほか. 腸脳連関と生活習慣病. アンチ・エイジング医学. 14 (6), 2018, 81-91.
 
13) Kozuka C, et al. Marked augmentation of PLGA nanoparticle-induced metabolically-beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice. Drug Deliv. 24 (1), 2017, 558-68.
 

書評

最近チェックした商品履歴

Loading...